Neurocrine settles INGREZZA patent litigation with Teva; generic entry allowed Feb 2040

NEUROCRINE BIOSCIENCES INC

Settlement grants Teva right to sell generic INGREZZA in the U.S. starting February 1, 2040, or earlier under certain conditions.
Agreement resolves ANDA patent litigation filed in District of Delaware; terms to be submitted to FTC and DOJ.
Patent litigation against three other ANDA filers for generic INGREZZA remains pending, trial scheduled for January 2, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.